Learn More
primary cause has been the Japanese Pharmaceuticals and Medical Devices Agency's (PMDA) requirement that drug companies conduct separate and additional safety studies in Japanese patients. That policy, though modifi ed recently, is based on safety concerns, Tamura said. Several studies have shown that Asians metabolize drugs differently from white patients,(More)
L ike many oncologists, Don Dizon, M.D., doesn't like to candy-coat bad news. " I try to be realistic about what we can accomplish with treatment, " said Dizon, who specializes in treating gyneco-logical cancers at Women and Infants Hospital of Rhode Island. But it's in what he tells his patients afterward that Dizon may stray from the norm. Dizon also(More)